The Commission today adopted the first annual work programme of Erasmus+ 2021-2027. With a budget of €26.2 billion, (compared to €14.7 billion for 2014-2020), complemented with about €2.2 billion from EU's external instruments, the new and revamped programme will fund learning mobility and cross-border cooperation projects for 10 million Europeans of all ages and all backgrounds. It will seek to be even more inclusive and to support the green and digital transitions, as set out in the European Education Area. Erasmus+ will also support the resilience of education and training systems in the face of the pandemic.
Today, the Commission presented an Action Plan for the development of organic production. Its overall aim is to boost the production and consumption of organic products, to reach 25% of agricultural land under organic farming by 2030, as well as to increase organic aquaculture significantly.
Today, the European Commission has introduced the principles of reciprocity and proportionality as new criteria to be considered for authorising exports under the transparency and authorisation mechanism for COVID-19 vaccine exports. This system has significantly improved the transparency of exports. Nevertheless, the objective to ensure timely access to COVID-19 vaccines for EU citizens is still not met.
The Commission has today adopted the first comprehensive EU Strategy on the Rights of the Child, as well as a proposal for a Council Recommendation establishing a European Child Guarantee, to promote equal opportunities for children at risk of poverty or social exclusion. In preparation of both initiatives, the Commission, in association with leading global child rights organisations, collected the views of over 10,000 children.
Today, the European Commission launched Open Research Europe, a publishing platform for scientific papers that will be accessible to everyone. The platform will present the results of research funded by Horizon Europe, the EU research and innovation programme for 2021-2027, and its predecessor, Horizon 2020.
Today, as an immediate action under the HERA Incubator, the new European bio-defence preparedness plan against COVID-19 variants, the Commission is introducing a measure to speed up the authorisation of adapted COVID-19 vaccines. It will make provisions in the relevant EU legislation to allow companies to focus on gathering the necessary evidence in time and enable the authorisation of adapted vaccines with a smaller set of additional data submitted to the European Medicines Agency.
The Commission has published its first preliminary assessment of the impact of SURE, the €100 billion instrument designed to protect jobs and incomes affected by the COVID-19 pandemic.